Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2019 / N 2

Фторхинолоны: вопросы эффективности и безопасности применения в пульмонологической практике
Н.Б. Лазарева, Е.В. Реброва, А.Ю. Рязанова, Д.Д. Савинцева

References

1. Clinical pharmacology. Kukes VG, Sychev DA, editors, 5th ed. Moscow: Geotar-Media; 2017. 1024 p. (In Russian).
2. Sidorenko SV. Fluoroquinolones: properties and clinical application. Difficult Patient 2011;9(5):21-7 (In Russian).
3. Felmingham D, Feldman C, Hryniewicz W, Klugman K, Kohno S, Low DE, Mendes C, Rodloff AC. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clinical Microbiology and Infection 2002;8(Suppl 2):12-42.
4. Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA; Gemifloxacin Surveillance Study Research Group. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagnostic Microbiology and Infectious Disease 2001 Apr-May;40(1-2):51-7.
5. Koeth LM, Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Appelbaum PC. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Unated States in 1999–2000. International Journal of Antimicrobial Agents 2002 Jan;19(1):33-7.
6. Kozlov RS, Sukhorukova MV, Sivaya OV, and study group PEGASus. Sensitivity to antimicrobial agents of clinical strains of Streptococcus pneumoniae from different regions of the RF in 2010–2013. Clinical Microbiology and Antimicrobial Chemotherapy 2015;17(2):31 (In Russian).
7. Kozlov RS, Sivaya OV, Krechikova OI, Ivanchyk NV, and study group PEGASus. Antimicrobial resistance of Streptococcus pneumoniae in Russia over 1999-2009: results of a multicenter prospective study PEGASus. Clinical Microbiology and Antimicrobial Chemotherapy 2010;12(4):329-41 (In Russian).
8. Sinopalnikov AI. Place of respiratory fluoroquinolones in treatment of community-acquired pneumonia: focus on high-dose levofloxacin therapy. Medical Council 2017;18:65-8 (In Russian).
9. Yakovlev SV. New concept of rational use of antibiotics in outpatient practice. Antibiotiki i Khimioterapiya 2019; 64(3-4):48-58 (In Russian).
10. Davis SL, Neuhauser MM, McKinnon PS. Quinolones. Available from: http://www.antimicrobe.org/d17.asp Accessed 2019 Oct 08.
11. Zanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Current Opinion in Pharmacology 2001 Oct;1(5):459-63.
12. Zinner SH, Lubenko IY, Gilbert D, Simmons K, Zhao X, Drlica K, Firsov AA. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. The Journal of Antimicrobial Chemotherapy 2003 Oct;52(4):616-22.
13. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005;65(7):949-91.
14. Jones M, Draghi D, Thornsberry C, Sahm D. A current perspective on S. pneumoniae and H. influenzae resistance trends in Europe: GLOBAL surveillance study, 2005. In: Proceedings of 16th ECCMID; 2006 Apr 01–04; Nice, France. Abstr.: 1629.
15. U.S. Food & Drug Administration. FDA approves safety labeling changes for fluoroquinolones. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm500325.htm Accessed 2019 Oct 08.
16. U.S. Food & Drug Administration. FDA updates warnings for fluoroquinolone antibiotics. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm Accessed 2019 Oct 08.
17. European Medicines Agency. Fluoroquinolone and quinolone antibiotics: PRAC recommends new restrictions on use following review of disabling and potentially long-lasting side effects. Press release 05/10/2018. Available from: www.ema.europa.eu/en/news/fluoroquinolone-quinolone-antibiotics-prac-recommends-new-restrictions-use-following-review Accessed 2019 Oct 08.
18. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003 May;58(5):377-82.
19. Douros A, Grabowski K, Stahlmann R. Safety issues and drug­drug interactions with commonly used quinolones. Expert Opinion on Drug Metabolism & Toxicology 2015 Jan;11(1):25­39.
20. U.S. Food & Drug Administration. FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Available from: www.fda.gov/Drugs/DrugSafety/ucm511530.htm Accessed 2019 Oct 08.
21. U.S. Food & Drug Administration. FDA briefing document. Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. November 5, 2015 г. The benefits and risks of systemic fluoroquinolone antibacterial drugs for the treatment of acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic bronchitis in patients who have chronic obstructive pulmonary disease (ABECB­COPD), and uncomplicated urinary tract infections (uUTI). Available at: https://www.pharmamedtechbi.com/~/media/Supporting%20Documents/The%20Pink%20Sheet%20DAILY/2015/November/Antimicrobial%20AC%20FDA%20briefing%2011515.pdf Accessed 219 Oct 08.
22. Nambiar S. FDA Introductory Remarks. Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee November 5, 2015. Available from: http://www.myquinstory.info/wp-content/uploads/2018/06/FDA-Anti-Infective-Drugs-Advisory-Committee-UCM477657-Transcript-110515.pdf Accessed 219 Oct 08.
23. Ushkalova EA, Zyryanov SK. Fluoroquinolones use restrictions in patients with uncomplicated infections and safety issues. Clinical Microbiology and Antimicrobial Chemotherapy 2017;19(3):208-13 (In Russian).
24. European Medicines Agency. Quinolone and fluoroquinolone medicinal products for systemic and inhalation use. Assessment report. Available from: https://www.ema.europa.eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-assessment-report_en.pdf Accessed 2019 Oct 08.
25. Rachina SA, Sinopalnikov AI. Clinical guidelines for community-acquired pneumonia in adults: version 2019. Practical Pulmonology 2018;3:8-13 (In Russian).
26. Ministry of Healthcare of the Russian Federation. The Union of Pediatricians of Russia. Acute bronchitis in children: clinical guidelines. ICD-10: J20. ID: KR381. Moscow, 2016. 26 p. (In Russian).
27. Macfarlane J, Prewett J, Guion A, Winte JH, Woodhead MA. Community acquired lower respiratory tract infection. Bacterial infection not uncommon. BMJ 1994 May;308(6938):1239.
28. Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. The Lancet 1993 Feb;341(8844):511-4.
29. Laurenzi GA, Potter RT, Kass EH. Bacteriologic flora of the lower respiratory tract. The New England Journal of Medicine 1961 Dec;265:1273-8.
30. Smith JM, Lockwood BM. Commensal or pathogen? The growing dilemma facing the general practitioner. The New Zealand Medical Journal 1986;99(799):242-3.
31. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ; Joint Task force of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections – full version. Clinical Microbiology and Infection 2011 Nov;17(Suppl 6):E1-59.
32. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Leven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJM. European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. The European Respiratory Journal 2005;26(6):138-80.
33. Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs & Aging 1999 Jul;15(1):15-28.
34. Stahlmann R, Lode HM. Safety considerations of fluoroquinolones in the elderly: an update. Drugs & Aging 2010 Mar;27(3):193-209.
35. Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opinion on Drug Safety 2013 Jul;12(4):497-505.
36. Wedzicha JA, Miravitlles M, Hurst JR, Calverley PM, Albert RK, Anzueto A, Criner GJ, Papi A, Rabe KF, Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson KC, Krishnan JA. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. The European Respiratory Journal 2017 Mar;49(3). pii: 1600791. doi: 10.1183/13993003.00791-2016. Print 2017 Mar.
37. Dever LL, Johanson WG Jr, Shashikumar K. Antibiotics in the treatment of acute exacerbations of chronic bronchitis. Expert Opinion on Investigational Drugs 2002 Jul;11(7):911-25.
38. Bandi V, Jakubowycz M, Kinyon C, Mason EO, Atmar RL, Greenberg SB, Murphy TF. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunology and Medical Microbiology 2003 Jun;37(1):69-75.
39. Fuso L, Incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G, Gliozzi F, Ciappi G. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. The American Journal of Medicine 1995 Mar;98(3):272-7.
40. Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respiratory Medicine 2013 Jan;107(1):10-22.
41. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease: intervention review. The Cochrane Collaboration: John Wiley & Sons; 2012. 61 p.
42. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995 Aug;108(2 Suppl):43S-52S.
43. Boselli E, Breilh D, Rimmelé T, Djabarouti S, Saux MC, Chassard D, Allaouchiche B. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Critical Care Medicine 2005 Jan;33(1):104-9.
44. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001 Apr;119(4):1114-22.
45. Koizumi F, Ohnishi A, Takemura H, Okubo S, Kagami T, Tanaka T. Effective monitoring of concentrations of ofloxacin in saliva of patients with chronic respiratory tract infections. Antimicrobial Agents and Chemotherapy 1994 May;38(5):1140-3.
46. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. The Journal of Antimicrobial Chemotherapy 1999 Dec;44(6):835-8.
47. Ministry of Healthcare of the Russian Federation, Russian Respiratory Society. Chronic obstructive pulmonary disease: clinical guidelines. ICD 10: J44. ID: CR603. Moscow, 2018; 76 p. (In Russian).
48. Nosocomial pneumonia in adults. Russian guidelines. Gelfand BR, editor. Moscow: MIA 2016; 176 p. (In Russian).
49. Hurley M, Smyth A. Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis. Therapeutic Advances in Respiratory Disease 2012 Dec;6(6):363-73.
50. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. The Lancet 1991 Sep;338(8769):725-6.
51. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Pediatrics and Adolescence Medicine 2011 Sep;165(9):847-56.
52. Kaehne A, Milan SJ, Felix LM, Sheridan E, Marsden PA, Spencer S. Head-to-head trials of antibiotics for bronchiectasis. Cochrane Database of Systematic Reviews 2018 Sep;(9):CD012590.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]